The carriers of the A/G-G/G allelic combination of the c.2039 A&gt;G and c.-29 G&gt;A FSH receptor polymorphisms retrieve the highest number of oocytes in IVF/ICSI cycles

Allegra, Adolfo; Marino, Angelo; Raimondo, Stefania; Maiorana, Antonio; Gullo, Salvatore; Scaglione, Piero; Volpes, Aldo; Alessandro, Riccardo

doi:10.1007/s10815-016-0835-9

Cited by 12 publications

(4 citation statements)

References 47 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FSHR :c.919G>A and FSHR :c.2039G>A were previously associated with variability in serum FSH levels and reproductive outcomes in different populations ( 11 – 13 , 15 , 30 – 34 ). These SNVs are located in the coding region of the FSHR gene and have been well characterized ( 13 ).…”

Section: Discussionmentioning

confidence: 86%

Effects of FSHR and FSHB Variants on Hormonal Profile and Reproductive Outcomes of Infertile Women With Endometriosis

et al. 2021

View full text Add to dashboard Cite

BackgroundSingle nucleotide variants (SNVs) FSHB:c.-211G>T, FSHR:c.919G>A, and FSHR:c.2039G>A were reported to be associated with the variability in FSH and LH levels, and in vitro fertilization (IVF) outcomes. In this study, we aimed to evaluate the effects of FSHB:c.-211G>T, FSHR:c.919G>A, and FSHR:c.2039G>A variants, alone and combined, on the hormonal profile and reproduction outcomes of women with endometriosis.MethodsA cross-sectional study was performed comprising 213 infertile Brazilian women with endometriosis who underwent IVF treatment. Genotyping was performed using TaqMan real-time PCR. Variables were compared according to the genotypes of each variant and genetic models, and the combined effects of the SNVs were evaluated using the multifactorial dimensionality reduction method.ResultsFSHB:c.-211G>T affected LH levels in women with overall endometriosis and minimal/mild disease. FSHR:c.919G>A affected FSH levels in women with overall endometriosis and the number of oocytes retrieved in those with moderate/severe endometriosis. Moreover, the FSHR:c.2039G>A affected FSH levels in women with overall endometriosis, LH levels and total amount of rFSH in those with minimal/mild disease, and number of follicles and number of oocytes retrieved in those with moderate/severe endometriosis. No effect on hormone profile or reproductive outcomes was observed when the genotypes were combined.ConclusionsVariants of the FSHB and FSHR genes separately interfered with the hormonal profiles and IVF outcomes of women with endometriosis.

show abstract

Section: Discussionmentioning

confidence: 86%

Effects of FSHR and FSHB Variants on Hormonal Profile and Reproductive Outcomes of Infertile Women With Endometriosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In a number of studies, rs6166 showed an association with basal FSH levels, the time required for stimulation [ 21 - 23 , 28 , 30 ], the number of retrieved oocytes [ 4 , 28 , 29 , 32 , 39 ], and implantation and pregnancy rates [ 40 ]. On the contrary, in other studies, rs6166 was reported to have no association with ovarian response, especially oocyte retrieval, pregnancy rate, and FSH levels [ 24 , 34 , 41 ]. The results of the present study are consistent with the findings of the majority of previous studies regarding the important role of this SNP in determining the response of women to ovarian stimulation.…”

Section: Discussionmentioning

confidence: 79%

Association of single-nucleotide polymorphisms in the ESR2 and FSHR genes with poor ovarian response in infertile Jordanian women

Sindiani

Batiha

Al‐zoubi

et al. 2021

Clin Exp Reprod Med

View full text Add to dashboard Cite

Objective: Poor ovarian response (POR) refers to a subnormal follicular response that leads to a decrease in the quality and quantity of the eggs retrieved after ovarian stimulation during assisted reproductive treatment (ART). The present study investigated the associations of multiple variants of the estrogen receptor 2 (ESR2) and follicle-stimulating hormone receptor (FSHR) genes with POR in infertile Jordanian women undergoing ART.Methods: Four polymorphisms, namely ESR2 rs1256049, ESR2 rs4986938, FSHR rs6165, and FSHR rs6166, were investigated in 60 infertile Jordanian women undergoing ART (the case group) and 60 age-matched fertile women (the control group), with a mean age of 33.60±6.34 years. Single-nucleotide polymorphisms (SNPs) were detected by restriction fragment length polymorphism and then validated using Sanger sequencing.Results: The p-value of the difference between the case and control groups regarding FSHR rs6166 was very close to 0.05 (p=0.054). However, no significant differences were observed between the two groups in terms of the other three SNPs, namely ESR2 rs1256049, ESR2 rs4986938, and FSHR rs6165 (p=0.561, p=0.433, and p=0.696, respectively).Conclusion: The association between FSHR rs6166 and POR was not statistically meaningful in the present study, but the near-significant result of this experiment suggests that statistical significance might be found in a future study with a larger number of patients.

show abstract

“…51 In a similar study in a Greek population, ESR1 Pvu II CC/AA genotypes and FSHR Ser680Asn polymorphisms were the worst, while the combination of TC/SA was the most favorable for achieving pregnancy after IVF. 102 A recent study has also shown that women homozygous for the serine amino acid (S) of both LHCGR Asn312Ser and FSHR Asn680Ser polymorphisms had an increased probability of pregnancy in IVF cycles, 103 while in another study women with the combination of A/G-G/G of c.2039A>G and c.-29G>A FSHR polymorphisms produced an increased number of oocytes after COS. 104 Of particular interest is also the possible interaction between polymorphisms in the AMH and FSHR genes in relation to the number of the mature oocytes produced. 50…”

Section: Gene Polymorphisms and Ovarian Response Following Controlled Ovarian Stimulationmentioning

confidence: 99%

Pharmacogenomics in IVF: A New Era in the Concept of Personalized Medicine

et al. 2019

View full text Add to dashboard Cite

Pharmacogenomics is a promising approach in the field of individualized medicine in in vitro fertilization (IVF) treatment that aims to develop optimized pharmacotherapy depending on the genetic background of each infertile woman, thus to ensure maximum effectiveness of the medication used, with minimal side effects. The unique genetic information of each infertile woman, in combination with already known, as well as new predictors of ovarian response and the progress of pharmacoepigenomics, is anticipated to greatly benefit the process of controlled ovarian stimulation. This review analyses current data on IVF pharmacogenomics, a new approach that is gradually moving to the frontline of modern IVF treatment.

show abstract

The carriers of the A/G-G/G allelic combination of the c.2039 A>G and c.-29 G>A FSH receptor polymorphisms retrieve the highest number of oocytes in IVF/ICSI cycles

Cited by 12 publications

References 47 publications

Effects of FSHR and FSHB Variants on Hormonal Profile and Reproductive Outcomes of Infertile Women With Endometriosis

Effects of FSHR and FSHB Variants on Hormonal Profile and Reproductive Outcomes of Infertile Women With Endometriosis

Association of single-nucleotide polymorphisms in the ESR2 and FSHR genes with poor ovarian response in infertile Jordanian women

Pharmacogenomics in IVF: A New Era in the Concept of Personalized Medicine

Contact Info

Product

Resources

About